At the prison hospital inside the California Men’s Colony near San Luis Obispo, 75-year-old Floyd Masterson is waiting to pick up some medication. He carries a walking stick in one hand and a pink appointment slip in the other. Like the rest of the inmates around him, he’s dressed in a dark blue prison uniform. He has something else in common with many prisoners: hepatitis C. The disease affects about 1 percent of the country’s population as a whole, but 17 percent of those in prison.
G. Scott Gazelle, MD, MPH, PhD, ITA director emeritus and vice chair for Faculty Affairs in the Department of Radiology, has received the 2016 Radiology Alliance for Health Services Research Achievement Award. The award honors the achievements of an individual who has made significant contributions to the field of health services research in radiology. Gazelle received the award during the Association of University Radiologists Annual Meeting.
Reston, VA — H. Benjamin Harvey, MD, JD, Massachusetts General Hospital, Boston, and Courtney C. Moreno, MD, Emory University, Atlanta, GA, are recipients of the American College of Radiology (ACR) 2016 Bruce J. Hillman Fellowship in Scholarly Publishing.
(HealthDay)—The burden of hepatitis C virus (HCV) and associated disease is projected to remain considerable even in the era of oral direct-acting antivirals (DAAs), according to a study published online March 25 in Hepatology.
The cost of treating hepatitis C (HCV) is likely to decline dramatically over the next decade in the United States, not because of cuts in drug prices but because the population in need of treatment will shrink by 2020 as a majority of patients will already have been treated, according to research by Jagpreet Chhatwal of Massachusetts General Hospital and colleagues presented at the 2015 AASLD Liver Meeting in San Francisco last month.